Melanoma

Melanoma Treatment Trials

Protocol
Number

Title

ID

Novartis
MEK
162A2301
SLUHN
2013-54

Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive melanoma.

Learn more.

NCT01763164
Genentech
Roche
GO27826

This multi-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in patients with completely resected, cutaneous BRAF-mutation positive melanoma at high risk for recurrence. Patients will be randomized to receive oral doses of vemurafenib 960 mg twice daily or matching placebo.

Learn more.

NCT01667419
BMS
CA184143

The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting.

Learn more.

NCT01511913

SLHN
2009-84
Provectus
PV10-
EA02

Open Label Expanded Access for Investigational Use of PV-10 in Patients who are not Eligible for an Existing PV-10 Clinical Trial for whom there is no Comparable or Satisfactory Approved Alternative Therapy & Whom in the Opinion of the Investigator may Benefit from PV-10 Administration


Learn more.
NCT 0120779

COLUMBUS CMEK162B2301
SLUHN 2014-24

A Phase III Randomized, 3-arm, Open Label, Multicenter Study of LGX818 Plus MEK162 and LGX818 Monotherapy Compared With Vemurafenib in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Learn more.

NCT01909453Mi

Millennium C28001
SLUHN 2014-47

An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma

Learn more.

NCT01425008
Takara
T14-10682
SLUHN 2014-66

A Phase II Study of Combination Treatment with HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Patients with Stage IIIB, Stage IIIC, or Stage IV Unresected or Metastatic Malignant Melanoma

Learn more.

NCT02272855
OncoSec
SLUHN 2014-84

Phase II Expansion Study;  OMS-I100: A Multicenter Phase II Trial of Intratumoral pIL-12 + Electroporation In Advanced Stage Cutaneous and In Transit Malignant Melanoma

Learn more.

NCT01502293
MISP 50442 SLUHN 2013-85

An Observational Pilot Study to Compare the Compliance with and Health Related Quality of Life during Therapy with Standard High-Dose Interferon Alfa (Intron® A, HDI) versus Pegylated Alfa-Interferon 2b (Sylatron™, PEG IFN) in Patients with Surgically Resected Melanoma

Learn more.

NCT01986712